Sakamoto Y, Morohashi H, Yoshida E, et al. Treatment Strategy for Stage Ⅳ Rectal Cancer. Gan To Kaqaku Ryoho. 2015,42:1313-1515.
 Russell MM, Ganz PA, Lopa S, et al. Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer: Patient-Reported Outcomes in National Surgical Adjuvant BrEast and Bowel Project Randomized Trial R-04. Ann Surg. 2015, 261:144-8
 F. Dumont, A. Mariani, D. Elias, D, et al. Surgical strategy for low rectal cancers. J Visc Surg. 2015, 152:739–744.
 Polanco PM, Mokdad AA, Zhu H, et al. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection. JAMA oncology. 2018,4:938-943.
 Cui Y, Yang X, Shi Z, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2019,29:1211-1220.
 Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004, 240:711–717.
 Li J, Li L, Yang J, et al. Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncotarget. 2016, 7:44857-44870.
 Dossa F, Chesnev TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenteol Hepatol. 2017,2:501-513.
 Buijo K, Rutkowski A. RE: Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer. J Natl Cancer Inst. 2016,108:djw291.
 Wells GA, Shea B, O’Connell D, et al. The Newcastle-Patent Scale (NOS) for assessing the quality of nonrandomised studies in meta- analyses. Ottawa Hospital Research Institute Web Site. http://www ohri ca/ programs/clinical epidemiology/oxford.asp. Accessed October 2017;25.
 Arauio RO, Valadão M, Borges D, et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015,41:1456-1463.
 Ayloor SR, Kondaveeti SS, Jayanand SB, et al. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided? Hepatogastroenterology. 2013, 60):410–414.
 Dalton RS, Velineni R, Osborne ME, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Colorectal Dis. 2012, 14:567-571.
 Lai CL, Lai MJ, Wu CC, et al. Rectal cancer with complete clinical response after neoadjuvant hemoradiotherapy, surgery, or "watch and wait" Int J Colorectal Dis. 2016, 31):413–419.
 Lee SY, Kim CH, Kim YJ, et al. Oncologic Outcomes according to Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradioation for Rectal Cancer. Oncology. 2015, 89:311–318.
 Li J, Liu H, Yin J, et al. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget. 2015, 6::4235–4261.
 Lin GP, Lee KD, Wang JY, et al. Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan. Asian J Surg. 2018, 41:203–206.
 Martens MH, Mass M, Heijnen LA, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016,108(12):djw171.
 Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011, 29:4633–4640.
 Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (theOnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016,17:174–183.
 Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012, 256:965–972.
 Smith RK, Fry RD, Mahmoud NN, et al. Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. Int J Colorectal Dis. 2015,30:769–774.
 Yeom SS, Lee SY, Kim CH, et al. Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy. Asian J Surg. 2019,42:823-831.
 Oldani A, Cesana G, Uccelli M, et al. Surgical outcomes of rectal resection: our 10 years experience. J Laparoendosc Adv Surg Tech A. 2019,29:820-825.
 Lu HT, Liu X, Shi G, et al. A comparative study of the minimal invasive surgery and radical surgery in low rectal cancer with almost-cCR(near-cCR) after neoadjuvant therapy. Modern Oncology. 2019,27:2900-2904.
 Aker M, Ganeshan B, Afaq A, et al. Magnetic resonance texture analysis in identifying complete pathological response to neoadjuvant treatment in locally advanced rectal cancer. Dis Colon Rectum. 2019,62:163-170.
 Li SJ, Wang L, Zhang XY, et al. Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy. Zhonghua Wei Chang Wai Ke Ze Zhi. 2019,22:648-655.
 Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017,390:469-479.